BNP Paribas Asset Management’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $24.8M | Sell |
303,685
-8,125
| -3% | -$587K | 0.02% | 534 |
|
|
2026
Q1 | $21.2M | Sell |
311,810
-335,775
| -52% | -$23.8M | 0.02% | 535 |
|
|
2025
Q4 | $49.2M | Sell |
647,585
-153,293
| -19% | -$11.1M | 0.06% | 304 |
|
|
2025
Q3 | $49.1M | Buy |
800,878
+11,384
| +1% | +$593K | 0.13% | 170 |
|
|
2025
Q2 | $38.6M | Buy |
789,494
+160,836
| +26% | +$7.64M | 0.09% | 216 |
|
|
2025
Q1 | $32M | Buy |
628,658
+44,332
| +8% | +$2.21M | 0.09% | 236 |
|
|
2024
Q4 | $26.4M | Buy |
584,326
+112,038
| +24% | +$4.8M | 0.07% | 283 |
|
|
2024
Q3 | $17.5M | Buy |
472,288
+26,773
| +6% | +$896K | 0.04% | 330 |
|
|
2024
Q2 | $13.6M | Buy |
445,515
+6,150
| +1% | +$199K | 0.04% | 366 |
|
|
2024
Q1 | $12.8M | Buy |
439,365
+35,173
| +9% | +$985K | 0.03% | 391 |
|
|
2023
Q4 | $11.1M | Sell |
404,192
-155,133
| -28% | -$3.55M | 0.03% | 404 |
|
|
2023
Q3 | $12.5M | Buy |
559,325
+31,379
| +6% | +$1.17M | 0.04% | 352 |
|
|
2023
Q2 | $21.5M | Sell |
527,946
-77,174
| -13% | -$3.78M | 0.07% | 281 |
|
|
2023
Q1 | $29.3M | Sell |
605,120
-25,230
| -4% | -$1.15M | 0.1% | 218 |
|
|
2022
Q4 | $24.1M | Buy |
630,350
+212,515
| +51% | +$8.83M | 0.09% | 264 |
|
|
2022
Q3 | $21M | Buy |
417,835
+107,993
| +35% | +$5.29M | 0.08% | 276 |
|
|
2022
Q2 | $12.4M | Buy |
309,842
+114,323
| +58% | +$4.01M | 0.05% | 372 |
|
|
2022
Q1 | $7.29M | Sell |
195,519
-22,559
| -10% | -$869K | 0.03% | 470 |
|
|
2021
Q4 | $8.69M | Buy |
218,078
+43,899
| +25% | +$1.68M | 0.03% | 473 |
|
|
2021
Q3 | $6.48M | Sell |
174,179
-93,898
| -35% | -$3.86M | 0.02% | 490 |
|
|
2021
Q2 | $11.3M | Sell |
268,077
-58,230
| -18% | -$2.5M | 0.04% | 412 |
|
|
2021
Q1 | $15.5M | Sell |
326,307
-118,119
| -27% | -$7.01M | 0.06% | 334 |
|
|
2020
Q4 | $27.1M | Sell |
444,426
-4,209
| -0.9% | -$248K | 0.13% | 197 |
|
|
2020
Q3 | $21M | Buy |
448,635
+58,425
| +15% | +$2.88M | 0.12% | 212 |
|
|
2020
Q2 | $19.8M | Buy |
390,210
+4,774
| +1% | +$235K | 0.13% | 187 |
|
|
2020
Q1 | $17.2M | Sell |
385,436
-20,521
| -5% | -$1.03M | 0.15% | 189 |
|
|
2019
Q4 | $19.5M | Buy |
405,957
+77,569
| +24% | +$3.3M | 0.13% | 208 |
|
|
2019
Q3 | $11.1M | Sell |
328,388
-61,949
| -16% | -$2.7M | 0.09% | 281 |
|
|
2019
Q2 | $17.6M | Buy |
390,337
+24,663
| +7% | +$974K | 0.14% | 196 |
|
|
2019
Q1 | $13.8M | Buy |
365,674
+121,257
| +50% | +$4.07M | 0.12% | 233 |
|
|
2018
Q4 | $7.82M | Buy |
244,417
+11,233
| +5% | +$404K | 0.07% | 327 |
|
|
2018
Q3 | $11M | Buy |
+233,184
| New | +$9.65M | 0.08% | 318 |
|
|
2015
Q2 | – | Sell |
-5,160
| Closed | -$314K | – | 1068 |
|
|
2015
Q1 | $314K | Sell |
5,160
-892
| -15% | -$54.4K | ﹤0.01% | 974 |
|
|
2014
Q4 | $313K | Buy |
+6,052
| New | +$266K | ﹤0.01% | 894 |
|
Other funds holding PTCT
RI
JT
BNP Paribas Asset Management's PTCT Position: Q2 2026 in Review
BNP Paribas Asset Management reduced its PTC Therapeutics (PTCT) stake by 2.6% in Q2 2026, selling an estimated $587K and leaving 303,685 shares worth $24.8M. The position accounts for 0.02% of the portfolio, ranked #534.
BNP Paribas Asset Management first reported a position in PTCT in Q4 2014 and has held it in 34 quarters since. The position peaked at $49.2M in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- BNP Paribas Asset Management held 303,685 shares of PTC Therapeutics worth $24.8M as of Q2 2026.
- BNP Paribas Asset Management sold 8,125 PTC Therapeutics shares in Q2 2026, an estimated $587K.
- PTC Therapeutics made up 0.02% of BNP Paribas Asset Management's portfolio in Q2 2026, its #534 holding.
- BNP Paribas Asset Management first reported a position in PTC Therapeutics in Q4 2014 and has held it in 34 quarters since.
- BNP Paribas Asset Management's PTC Therapeutics position peaked at $49.2M in Q4 2025.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on BNP Paribas Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.